The
global in-vitro toxicity testing market
since 2014 and the market is poised to grow by USD 2.39 billion during
2019-2023, progressing at a CAGR of almost 7% during the forecast period.
The market is driven by the increasing use of in-vitro toxicity testing
by companies to reduce drug failures. In addition, advances in toxicology are
anticipated to further boost the growth of the in-vitro toxicity testing
market.
The increasing use of in-vitro toxicity testing to reduce drug failures
will be one of the major drivers in the global market. The most common reason
for the rejection of drugs in the last phase of development is toxicity. Thus,
it is essential to adopt in-vitro toxicity testing as it reveals the species,
organ, and dose-specific toxic effects of drugs. It also helps avoid adverse
effects in patients who consume drugs for stomach pains, weakness, hand
tremors, ataxia, diarrhea, dizziness and in rare cases, heart problems. Thus, the
use of in-vitro toxicity testing to reduce drug failures will drive market
growth during the forecast period.
Buy 1 Technavio report and get the
second for 50% off. Buy 2 Technavio reports and get the third for free.
View market snapshot before purchasing
View market snapshot before purchasing
Major Five In-Vitro Toxicity Testing Market Companies:
Abbott Laboratories
Abbott Laboratories operates the business under various segments such as
established pharmaceuticals, nutritionals, diagnostics, cardiovascular and
neuromodulation, and others. The product offered by the company is Alere Triage
Drugs of Abuse Plus TCA Panel. This product is offered as an immunoassay used
for the qualitative determination of the presence of the major metabolites of
drugs of abuse.
Agilent Technologies Inc.
Agilent Technologies Inc. operates the business under three segments,
which include life sciences and applied markets; diagnostics and genomics; and
Agilent CrossLab. The company’s key offering includes MitoXpress Xtra Oxygen
Consumption Assay.
Bio-Rad Laboratories Inc.
Bio-Rad Laboratories Inc. has business operations under the life science
and clinical diagnostics segment. The product offered by the company is
Bio-Plex Pro RBM Human Kidney Toxicity Assay.
CELTHER POLSKA Sp z o.o.
CELTHER POLSKA Sp z o.o. operates the business under its unified
business segment. The company offers services such as hepatotoxicity testing,
neurotoxicity testing, and cardiotoxicity testing.
Charles River Laboratories International Inc.
Charles River Laboratories International Inc. operates the business
under the following segments: research models and services; discovery and
safety assessment; and manufacturing support. The company’s key offering in the
in-vitro toxicity testing market include genetic toxicity testing.
No comments:
Post a Comment